biguanides has been researched along with Cardiovascular Diseases in 27 studies
Biguanides: Derivatives of biguanide (the structure formula HN(C(NH)NH2)2) that are primarily used as oral HYPOGLYCEMIC AGENTS for the treatment of DIABETES MELLITUS, TYPE 2 and PREDIABETES.
biguanides : A class of oral hypoglycemic drugs used for diabetes mellitus or prediabetes treatment. They have a structure based on the 2-carbamimidoylguanidine skeleton.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study represents a new insight into the Biguanides and the Prevention of the Risk of Obesity (BIGPRO) 1 study population at inclusion." | 7.71 | Accumulation of triglyceride-rich lipoprotein in subjects with abdominal obesity: the biguanides and the prevention of the risk of obesity (BIGPRO) 1 study. ( André, P; Bard, JM; Charles, MA; Eschwege, E; Fruchart, JC; Juhan-Vague, I; Safar, M; Vague, P, 2001) |
| "The present study represents a new insight into the Biguanides and the Prevention of the Risk of Obesity (BIGPRO) 1 study population at inclusion." | 3.71 | Accumulation of triglyceride-rich lipoprotein in subjects with abdominal obesity: the biguanides and the prevention of the risk of obesity (BIGPRO) 1 study. ( André, P; Bard, JM; Charles, MA; Eschwege, E; Fruchart, JC; Juhan-Vague, I; Safar, M; Vague, P, 2001) |
| " As an essential complication provoked by biguanides a lactic acidosis may be elicited which--though seldom occurring--then in most cases takes a fatal course." | 3.67 | [Drug-induced harm due to antidiabetics]. ( Verlohren, HJ, 1984) |
| "Type 2 diabetes mellitus is an increasingly prevalent disorder associated with multiple metabolic derangements." | 2.42 | Insulin sensitizers. ( Basu, A; Kudva, YC; Zangeneh, F, 2003) |
| "Optimal treatment for type 2 diabetes mellitus should aim to improve insulin resistance and the associated cardiovascular risk factors in addition to achieving glycaemic control." | 2.41 | Antidiabetic drugs present and future: will improving insulin resistance benefit cardiovascular risk in type 2 diabetes mellitus? ( Campbell, IW, 2000) |
| "Individuals with type 2 diabetes (T2DM) are at increased risk of cardiovascular disease, including heart failure (HF)." | 1.39 | Metformin treatment may be associated with decreased levels of NT-proBNP in patients with type 2 diabetes. ( Czlonkowski, A; Filipiak, KJ; Kaplon-Cieslicka, A; Opolski, G; Postula, M; Rosiak, M; Trzepla, E, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (40.74) | 18.7374 |
| 1990's | 1 (3.70) | 18.2507 |
| 2000's | 8 (29.63) | 29.6817 |
| 2010's | 7 (25.93) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Komamine, M | 1 |
| Kajiyama, K | 1 |
| Ishiguro, C | 1 |
| Uyama, Y | 1 |
| Rosiak, M | 1 |
| Postula, M | 1 |
| Kaplon-Cieslicka, A | 1 |
| Trzepla, E | 1 |
| Czlonkowski, A | 1 |
| Filipiak, KJ | 1 |
| Opolski, G | 1 |
| Tanabe, M | 1 |
| Nomiyama, T | 1 |
| Motonaga, R | 1 |
| Murase, K | 1 |
| Yanase, T | 1 |
| Pryor, R | 1 |
| Cabreiro, F | 1 |
| Waltenberger, B | 1 |
| Mocan, A | 1 |
| Šmejkal, K | 1 |
| Heiss, EH | 1 |
| Atanasov, AG | 1 |
| Saha, SA | 1 |
| Tuttle, KR | 1 |
| Chaudhuri, A | 1 |
| Dandona, P | 1 |
| Zangeneh, F | 1 |
| Kudva, YC | 1 |
| Basu, A | 1 |
| Iwamoto, Y | 1 |
| Uwaifo, GI | 1 |
| Ratner, RE | 1 |
| Moulin, P | 1 |
| Batsis, JA | 1 |
| Nieto-Martinez, RE | 1 |
| Lopez-Jimenez, F | 1 |
| Jellinger, PS | 1 |
| Verlohren, HJ | 1 |
| Paterson, KR | 1 |
| Paice, BJ | 1 |
| Lawson, DH | 1 |
| Haffner, SM | 1 |
| Campbell, IW | 1 |
| Bard, JM | 1 |
| Charles, MA | 1 |
| Juhan-Vague, I | 1 |
| Vague, P | 1 |
| André, P | 1 |
| Safar, M | 1 |
| Fruchart, JC | 1 |
| Eschwege, E | 1 |
| Biron, P | 1 |
| Stowers, JM | 3 |
| Borthwick, LJ | 2 |
| Taft, P | 1 |
| Ennis, G | 1 |
| Farid, NR | 1 |
| Marble, A | 1 |
| Ito, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effectiveness of the Treatment With Dapagliflozin and Metformin Compared to Metformin Monotherapy for Weight Loss on Diabetic and Prediabetic Patients With Obesity Class III[NCT03968224] | Phase 2/Phase 3 | 90 participants (Anticipated) | Interventional | 2018-07-07 | Recruiting | ||
| "Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Metformin, an Activator of AMPK, on Cognitive Measures of Progression in Huntington's Disease Patients"[NCT04826692] | Phase 3 | 60 participants (Anticipated) | Interventional | 2021-12-10 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
16 reviews available for biguanides and Cardiovascular Diseases
| Article | Year |
|---|---|
Repurposing metformin: an old drug with new tricks in its binding pockets.
Topics: Biguanides; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Metformin; Neoplasms; Protei | 2015 |
Repurposing metformin: an old drug with new tricks in its binding pockets.
Topics: Biguanides; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Metformin; Neoplasms; Protei | 2015 |
Repurposing metformin: an old drug with new tricks in its binding pockets.
Topics: Biguanides; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Metformin; Neoplasms; Protei | 2015 |
Repurposing metformin: an old drug with new tricks in its binding pockets.
Topics: Biguanides; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Metformin; Neoplasms; Protei | 2015 |
Natural Products to Counteract the Epidemic of Cardiovascular and Metabolic Disorders.
Topics: Biguanides; Biological Products; Cardiovascular Diseases; Drug Discovery; Humans; Hydroxymethylgluta | 2016 |
Influence of glycemic control on the development of diabetic cardiovascular and kidney disease.
Topics: Acarbose; Biguanides; Cardiovascular Diseases; Combined Modality Therapy; Contraindications; Diabete | 2010 |
Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes.
Topics: Biguanides; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Pe | 2011 |
Insulin sensitizers.
Topics: Biguanides; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin | 2003 |
[Selection of oral antidiabetic drugs].
Topics: Acarbose; Administration, Oral; Biguanides; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Enzy | 2005 |
Differential effects of oral hypoglycemic agents on glucose control and cardiovascular risk.
Topics: Administration, Oral; Benzamides; Biguanides; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Gl | 2007 |
Metabolic syndrome: from global epidemiology to individualized medicine.
Topics: Anti-Obesity Agents; Bariatric Surgery; Biguanides; Body Mass Index; Caloric Restriction; Cardiovasc | 2007 |
Metabolic consequences of hyperglycemia and insulin resistance.
Topics: Biguanides; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Dyslipidemias; Fatty Acids, No | 2007 |
Undesired effects of biguanide therapy.
Topics: Acidosis; Biguanides; Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Drug Interact | 1984 |
The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease.
Topics: Acarbose; Adult; Aged; Aged, 80 and over; Arteriosclerosis; Biguanides; Blood Glucose; Cardiovascula | 1998 |
Antidiabetic drugs present and future: will improving insulin resistance benefit cardiovascular risk in type 2 diabetes mellitus?
Topics: Biguanides; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Risk Fac | 2000 |
Oral hypoglycaemic drugs: clinical pharmacology and therapeutic use.
Topics: Acidosis; Animals; Biguanides; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; H | 1977 |
Oral treatment in diabetes.
Topics: Acetohexamide; Acidosis; Administration, Oral; Animals; Biguanides; Cardiovascular Diseases; Chlorpr | 1972 |
Pharmacology of antihyperglycemic drugs.
Topics: Administration, Oral; Biguanides; Cardiovascular Diseases; Diabetes Mellitus; Female; Humans; Hyperg | 1972 |
[Oral antidiabetics].
Topics: Acidosis; Biguanides; Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Gastrointesti | 1972 |
1 trial available for biguanides and Cardiovascular Diseases
| Article | Year |
|---|---|
Diabetic hearts and biguanides.
Topics: Animals; Biguanides; Canada; Cardiovascular Diseases; Clinical Trials as Topic; Cyclic AMP; Diabetes | 1975 |
10 other studies available for biguanides and Cardiovascular Diseases
| Article | Year |
|---|---|
Cardiovascular risks associated with dipeptidyl peptidase-4 inhibitors monotherapy compared with other antidiabetes drugs in the Japanese population: A nationwide cohort study.
Topics: Administrative Claims, Healthcare; Adolescent; Adult; Aged; Aged, 80 and over; Biguanides; Cardiovas | 2019 |
Metformin treatment may be associated with decreased levels of NT-proBNP in patients with type 2 diabetes.
Topics: Adrenergic beta-Antagonists; Aged; Atherosclerosis; Biguanides; Cardiovascular Diseases; Coronary Ar | 2013 |
Reduced vascular events in type 2 diabetes by biguanide relative to sulfonylurea: study in a Japanese Hospital Database.
Topics: Adult; Aged; Angina Pectoris; Biguanides; Cardiovascular Diseases; Cerebral Hemorrhage; Cerebral Inf | 2015 |
[Metabolically designed treatments: from biochemistry to the vessel lining].
Topics: Biguanides; Cardiovascular Agents; Cardiovascular Diseases; Clofibric Acid; Humans; Hydroxymethylglu | 2007 |
[Drug-induced harm due to antidiabetics].
Topics: Abnormalities, Drug-Induced; Acidosis; Biguanides; Bone Marrow; Cardiovascular Diseases; Chemical an | 1984 |
Accumulation of triglyceride-rich lipoprotein in subjects with abdominal obesity: the biguanides and the prevention of the risk of obesity (BIGPRO) 1 study.
Topics: Abdomen; Adult; Aged; Biguanides; Biomarkers; Cardiovascular Diseases; Endothelium, Vascular; Female | 2001 |
Oral hypoglycaemic agents.
Topics: Biguanides; Cardiovascular Diseases; Diabetes Mellitus; Humans; Hypoglycemic Agents; Sulfonylurea Co | 1979 |
Rational use of oral hypoglycaemic drugs.
Topics: Biguanides; Cardiovascular Diseases; Chemical Phenomena; Chemistry; Drug Interactions; Humans; Hypog | 1979 |
Oral hypoglycaemic agents--dangers and contraindications.
Topics: Aged; Biguanides; Cardiovascular Diseases; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; L | 1976 |
Letter: Fibrinolytic activity and treatment of diabetes.
Topics: Biguanides; Cardiovascular Diseases; Diabetes Mellitus; Diet; Female; Fibrinolysis; Humans; Insulin; | 1974 |